Article Text

Download PDFPDF

782-D Systemic delivery of novel, allosteric STING agonist CRD3874-SI leads to robust anti-cancer activity by generating pro-inflammatory Type I IFN signals while blocking proton channel mediated toxicity
  1. Monali Banerjee1,
  2. Sandip Middya1,
  3. Ritesh Shrivastava1,
  4. Anindita Middya1,
  5. Nagaswamy Mane1,
  6. Nidhi Rawat1,
  7. Thanilsana Soram1,
  8. Debjani Chakraborty1,
  9. Rajib Ghosh1,
  10. Rubeena Rais Mansuri1,
  11. Dharmendra Yadav1,
  12. Anuj Gautam1,
  13. Anuj Singh1,
  14. Kavita Puniya1,
  15. David Pryde2,
  16. Sourav Basu1,
  17. Fabiane Sonego3,
  18. Gaelle Martin3,
  19. Perrine Martin-Jeantet3,
  20. Angela Pappalardo3,
  21. Kader Thiam3,
  22. Ciara Kelly4 and
  23. Arjun Surya1
  1. 1Curadev, Noida, UP, India
  2. 2Curadev, Sandwich, Kent, UK
  3. 3genOway, Lyon, France
  4. 4MSKCC, New York, NY, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background STING activates Type1 interferon and pro-inflammatory responses to drive anti-tumor immunity. Current STING agonists under clinical investigation show limited efficacy due to safety considerations that prevent systemic administration. CRD3874-SI, a novel allosteric systemically safe small molecule STING agonist, addresses these shortcomings by blocking STING’s proton channel activity associated with runaway inflammation.

Methods Anti-cancer activity of CRD3874-SI by the IV route was evaluated in human STING KI C57/BL6 mice (Genoway) in various murine tumor models. PBMCs were used to measure cytokine levels and THP1 cells were used for the measurement of autophagy and inflammasome markers.

Results Intravenous administration of CRD3874-SI in human STING knock-in mice caused tumor regression in several cold tumor models such as B16F10, PANO2, LL2, C1498. The compound was well tolerated at high doses in the primate GLP study when administered intravenously and caused dose and exposure dependent increases in CXCL10. This profile of retaining the high efficacy of a STING agonist while demonstrating systemic safety is unique to CRD3874-SI. The mechanism for this unusually high safety margin may be attributed to CRD3874’s ability to block STING’s proton channel activity and prevent the release of inflammasome promoting cytokines such as IL1.

Conclusions The ability of CRD3874-SI to generate impressive anti-tumor immune responses in cold tumors as a single agent coupled with its excellent IV safety profile in non-human primates make it a differentiated next generation STING agonist. An investigator sponsored FIH Phase 1 trial with CRD3874-SI has been initiated at Memorial Sloan Kettering, NY, in sarcoma, MCC patients under the supervision of Dr. Ciara Kelly (NCT06021626).

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.